Previous 10 | Next 10 |
Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies PR Newswire WASHINGTON , March 7, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global ...
2023-03-06 07:00:00 ET Summary In this article, we discuss one of my favorite dividend growth stocks, which makes up for a low yield by being a consistent source of outperforming total returns. The company has a stellar high-moat M&A-driven business model with strong pricing p...
2023-03-05 05:11:06 ET Summary Danaher has benefited from the Covid-19 period. The company has seen strong (earnings) growth, and it's positioned to maintain this. Interesting deals have been pursued and leverage is very reasonable. Appeal is luring here at a 22-23 times e...
Summary Revenue should benefit from a healthy backlog, good end-market demand, China's economic reopening, and new product innovations. Margins should benefit from price increases, volume leverage, and easing supply chain conditions. Valuation multiple can re-rate higher which coupl...
Summary We start with a discussion of diversification theories based on the findings of a scientific article called "The Dividend Puzzle". While inexperienced investors should stick to ETFs, there's a clear case to be made for the behavioral approach, which is based on a mix of differen...
Summary Quarter over quarter dividend growth clocked in at 42.7% for February 2023. Due to ethical concerns, I exited all of my REIT positions and added four new positions to my portfolio. Seven of my portfolio companies increased their dividends since my last article and I'm antici...
Summary Hospital capital spending demand is strong, but Siemens Healthineers posted a small yet broad miss across its major business units for the fiscal first quarter. Imaging is performing well and Varian and Advanced Therapies were compromised by supply chain challenges, but core und...
Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend C...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Durable Advantage Fund gained 4.7% (Institutional Shares) in the fourth quarter, compared to the 7.6% gain fo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...